Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) EBT (2016 - 2025)

Historic EBT for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to $147.2 million.

  • BeOne Medicines' EBT rose 24970.3% to $147.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.3 million, marking a year-over-year increase of 12282.78%. This contributed to the annual value of -$533.0 million for FY2024, which is 3545.92% up from last year.
  • Latest data reveals that BeOne Medicines reported EBT of $147.2 million as of Q3 2025, which was up 24970.3% from $99.5 million recorded in Q2 2025.
  • BeOne Medicines' EBT's 5-year high stood at $229.3 million during Q3 2023, with a 5-year trough of -$606.0 million in Q4 2021.
  • Its 5-year average for EBT is -$237.4 million, with a median of -$336.9 million in 2023.
  • In the last 5 years, BeOne Medicines' EBT tumbled by 78091.65% in 2022 and then skyrocketed by 24970.3% in 2025.
  • BeOne Medicines' EBT (Quarter) stood at -$606.0 million in 2021, then increased by 28.89% to -$431.0 million in 2022, then grew by 18.61% to -$350.8 million in 2023, then skyrocketed by 75.67% to -$85.4 million in 2024, then surged by 272.42% to $147.2 million in 2025.
  • Its last three reported values are $147.2 million in Q3 2025, $99.5 million for Q2 2025, and $20.9 million during Q1 2025.